Literature DB >> 3119600

A model of localized osteolysis induced by the MBT-2 tumor in mice and its responsiveness to etidronate disodium.

R Nemoto1, K Uchida, M Tsutsumi, K Koiso, S Satou, T Satou.   

Abstract

A new experimental method to test the effect of drugs on tumor-induced osteolysis using a bladder tumor in mice has been designed. The method consisted of inoculating MBT-2 tumor cells s.c. over the calvaria in mice, resulting in a local tumor causing fragmentation of the bone. This was accompanied by adjacent osteoplastic changes, which were evaluated by X-ray and histological examination. Etidronate disodium (EHDP), a diphosphonate derivative, at a dose of 3 mg/kg to 30 mg/kg s.c. protected the bone by decreasing the extent of osteolysis as judged by the same criteria. Therapy with EHDP prolonged the survival period. This inhibition was obtained with no apparent effect on the growth of the MBT-2 tumor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119600     DOI: 10.1007/bf00390862

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  17 in total

1.  Bone lesions produced by transplanted plasma-cell tumors in BALB/c mice.

Authors:  H KOBAYASHI; M POTTER; T B DUNN
Journal:  J Natl Cancer Inst       Date:  1962-03       Impact factor: 13.506

2.  Relationship of bone destruction in skeletal metastases to osteoclast activation and prostaglandins.

Authors:  C S Galasko; A Bennett
Journal:  Nature       Date:  1976-10-07       Impact factor: 49.962

3.  The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats.

Authors:  R G Russell; R C Mühlbauer; S Bisaz; D A Williams; H Fleisch
Journal:  Calcif Tissue Res       Date:  1970

4.  Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation.

Authors:  A I Cohen; J Koeller; T E Davis; D L Citrin
Journal:  Cancer Treat Rep       Date:  1981 Jul-Aug

5.  Effects of disodium etidronate in murine tumor models.

Authors:  A Guaitani; N Polentarutti; S Filippeschi; L Marmonti; F Corti; C Italia; G Coccioli; M G Donelli; A Mantovani; S Garattini
Journal:  Eur J Cancer Clin Oncol       Date:  1984-05

6.  Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases.

Authors:  M C Chapuy; P J Meunier; C M Alexandre; E P Vignon
Journal:  J Clin Invest       Date:  1980-05       Impact factor: 14.808

7.  Effects of dichloromethylene diphosphonate on the osteolytic and osteoplastic effects of rat prostate adenocarcinoma cells.

Authors:  M Pollard; P H Luckert
Journal:  J Natl Cancer Inst       Date:  1985-11       Impact factor: 13.506

8.  The effect of prostaglandin synthesis inhibitors and diphosphonates on tumour-mediated osteolysis.

Authors:  C S Galasko; A W Samuel; S Rushton; E Lacey
Journal:  Br J Surg       Date:  1980-07       Impact factor: 6.939

9.  Inhibition by two diphosphonates of bone lysis in tumor-conditioned media.

Authors:  A Jung; B Mermillod; C Barras; M Baud; B Courvoisier
Journal:  Cancer Res       Date:  1981-08       Impact factor: 12.701

10.  The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer.

Authors:  T J Powles; S A Clark; D M Easty; G C Easty; A M Neville
Journal:  Br J Cancer       Date:  1973-10       Impact factor: 7.640

View more
  7 in total

1.  Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.

Authors:  Andreas A Kurth; Soo-Zin Kim; Marie Shea; Frieder Bauss; Wilson C Hayes; Ralph Müller
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 3.  Antitumour effects of bisphosphonates: first evidence and possible mechanisms.

Authors:  I J Diel
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

Review 4.  Current role of bone scan with phosphonates in the follow-up of breast cancer.

Authors:  Lorenzo Maffioli; Luigia Florimonte; Luca Pagani; Ivana Butti; Isabel Roca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-16       Impact factor: 9.236

5.  New bone formation and cancer implants; relationship to tumour proliferative activity.

Authors:  R Nemoto
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

Review 6.  Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG).

Authors:  I J Diel; G R Mundy
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

7.  Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.

Authors:  R Nemoto; Y Nishijima; K Uchida; K Koiso
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.